Else Kröner Forschungskolleg Cologne

Modern-day cancer therapy is witnessing a paradigmatic shift, away from globally toxic chemo- and radiotherapy, towards the use of non-genotoxic targeted small molecules and antibodies. These efforts are rooted in a steadily deepening molecular understanding of the patho-mechanisms underlying malignant transformation. The advent of modern technologies, particularly genome sequencing and novel approaches in high-performance computational biology, has revolutionized cancer research. These knowledge gains led to the development and clinical implementation of numerous novel drugs that specifically target genotype-stratified tumor entities. Prime examples are the use of specific tyrosine kinase inhibitors for EGFR-mutant-, EML4-ALK-rearranged- or ROS1-rearranged tumors, as well as BCR-ABL-fused leukemia.

These groundbreaking developments necessitate a profound change in the training and education of young oncologists. These physicians need solid clinical skills and a thorough training in molecular cancer research. Thus, we carefully assembled a peerless consortium of clinical opinion leaders and internationally competitive cancer researchers to create a structured training program for physician scientists that aim for a career in translational oncology.

Our consortium is tailored to address the question of clonal evolution and selection in response to targeted therapy. We consider this overarching question to be the major challenge in modern-day cancer therapy, as the majority of targeted approaches are eventually limited by the occurrence of acquired drug resistance. Our proposal is a cross-faculty joint effort of the members of the Center for Cancer and Immunology Research at the comprehensive cancer center of the University Cologne (CIO-CCIR) and also involves a non-university research center (Max-Planck-Institute for Metabolism Research). 


Sven Borchmann publishes paper on active surveillance in nodular lymphocyte-predominant Hodgkin lymphoma in Blood

The Else Kröner Forschungskolleg Cologne fellow Sven Borchmann has published his paper titled “Active surveillance for nodular lymphocyte-predominant...

Ron Jachimowicz´s paper on UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors is published

The Else Kröner Forschungskolleg Cologne fellow Ron Jachimowicz has published his paper in Cell.

Prof. Matthias Fischer publishes his work on the mechanistic classification of clinical phenotypes in neuroblastoma

Principal Investigator at the Else Kröner Forschungskolleg Cologne publishes in Sciene. The EKF fellow, Carolina Rosswog, has contributed to this...

Else Kröner Forschungskolleg Cologne 1st Annual Retreat

Annual Retreat on 19th of October 2018


20th International AEK Cancer Congress, Feburary 27th - March 1st 2019

Translating Cancer Biology: From Basic Mechanism to Therapeutic Exploitation

IABCR 2019, April 15th-18th 2019

31st International Association for Breast Cancer Research Conference

9th Mildred Scheel Cancer Conference, May 15th-16th 2019

9th Cancer Conference by Deutsche Krebshilfe

Cologne Cancer Club, March 7th 2019

Defining epi-transcriptome gene networks and cancer vulnerabilities

1st German Cancer Research Congress, February 4th–5th 2019

Scientific program and presentation of innovative research results

BIO.NRW.academy, January 31st 2019

Digitalisierung in den Life Sciences am Beispiel des Next Generation Sequencing